{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:46Z","timestamp":1790717146110,"version":"4.1.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine and Surgery"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.amsu.2021.102799","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:02:20Z","timestamp":1630720940000},"page":"102799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions"],"prefix":"10.1097","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-6438","authenticated-orcid":false,"given":"Subaina Naeem","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeest Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hamza","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-600X","authenticated-orcid":false,"given":"Talal","family":"Almas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-3442","authenticated-orcid":false,"given":"Tarek","family":"Khedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikneswaran","family":"Raj Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.amsu.2021.102799_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.iac.2012.04.002","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"32","author":"Schmidt","year":"2012","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.amsu.2021.102799_bib2","author":"Amber"},{"key":"10.1016\/j.amsu.2021.102799_bib3","first-page":"220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations the general epidemiology OF BP","volume":"1","author":"Shear","year":"2018","journal-title":"Front. Med. | Www.Frontiersin.Org."},{"key":"10.1016\/j.amsu.2021.102799_bib4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaad.2018.08.030","article-title":"Prevalence estimates for pemphigoid in the United States: a sex-adjusted and age-adjusted population analysis","volume":"80","author":"Wertenteil","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bjd.19022","article-title":"British journal of dermatology incidence, prevalence and mortality of bullous pemphigoid in england 1998-2017 linked comment: bax and werth","volume":"184","author":"Persson Id","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib6","first-page":"1","article-title":"Emerging treatments for bullous pemphigoid","author":"Garrido","year":"2021","journal-title":"The Journal of dermatological treatment"},{"key":"10.1016\/j.amsu.2021.102799_bib7","author":"Kasperkiewicz"},{"key":"10.1016\/j.amsu.2021.102799_bib8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1346-8138.2009.00792.x","article-title":"What's new in bullous pemphigoid","volume":"37","author":"Ujiie","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies","volume":"31","author":"Lo Schiavo","year":"2013","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib10","first-page":"1506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"1","author":"Bieber","year":"2019","journal-title":"Front. Immunol. | Www.Frontiersin.Org."},{"key":"10.1016\/j.amsu.2021.102799_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp. Dermatol."},{"issue":"7","key":"10.1016\/j.amsu.2021.102799_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.amsu.2021.102799_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.amsu.2021.102799_bib14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1684\/ejd.2018.3366","article-title":"Immunoglobulin E and bullous pemphigoid","volume":"28","author":"Cozzani","year":"2018","journal-title":"European journal of dermatology : EJD"},{"key":"10.1016\/j.amsu.2021.102799_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","author":"Amber","year":"2018","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.amsu.2021.102799_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2133.2008.08858.x","article-title":"IgE autoantibodies against the intracellular domain of BP180","volume":"160","author":"Dresow","year":"2009","journal-title":"The British journal of dermatology"},{"key":"10.1016\/j.amsu.2021.102799_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid","volume":"49","author":"Ishiura","year":"2008","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.amsu.2021.102799_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"The Journal of investigative dermatology"},{"issue":"2","key":"10.1016\/j.amsu.2021.102799_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2101","article-title":"Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta dermato-venereologica"},{"issue":"1","key":"10.1016\/j.amsu.2021.102799_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.amsu.2021.102799_bib21","series-title":"Factors associated with the activity and severity of bullous pemphigoid: a review","first-page":"55","author":"Liu","year":"2020"},{"issue":"5","key":"10.1016\/j.amsu.2021.102799_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmunity reviews"},{"issue":"1","key":"10.1016\/j.amsu.2021.102799_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"The British journal of dermatology"},{"issue":"2","key":"10.1016\/j.amsu.2021.102799_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","article-title":"Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid","volume":"83","author":"Fang","year":"2016","journal-title":"Journal of dermatological science"},{"key":"10.1016\/j.amsu.2021.102799_bib25","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3389\/fimmu.2019.01972","article-title":"IL-23\/IL-17 Axis Activates IL-1\u03b2-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid","author":"Le Jan","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.amsu.2021.102799_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Experimental dermatology"},{"key":"10.1016\/j.amsu.2021.102799_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amsu.2021.102799_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2165\/00002512-200522070-00003","article-title":"The role of topical corticosteroids in bullous pemphigoid in the elderly","volume":"22","author":"Joly","year":"2005","journal-title":"Drugs Aging"},{"issue":"10","key":"10.1016\/j.amsu.2021.102799_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004056","article-title":"Interventions for bullous pemphigoid","volume":"2010","author":"Kirtschig","year":"2010","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1016\/j.amsu.2021.102799_bib30","unstructured":"P. Joly, Safety and efficacy of a 0.5 mg\/kg\/day dose of prednisone as initial treatment of bullous pemphigoid, (n.d.). https:\/\/eadv.org\/project- (accessed July 26, 2021)."},{"key":"10.1016\/j.amsu.2021.102799_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-017-0264-2","article-title":"\u2022 frank antonicelli, bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid","volume":"147","author":"Wojnarowska","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.15816","article-title":"Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment","volume":"48","author":"Ujiie","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archderm.1984.01650450039014","article-title":"High-dose methylprednisolone in the treatment of bullous pemphigoid","volume":"120","author":"Siegel","year":"1984","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib35","series-title":"Cochrane Library Cochrane Database of Systematic Reviews Interventions for Bullous Pemphigoid (Review)","author":"KirtschigG","year":"2016"},{"key":"10.1016\/j.amsu.2021.102799_bib36","unstructured":"Bullous Pemphigoid: Clinical Practice Guidelines | Elsevier Enhanced Reader, (n.d.). https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S1578219014000778?token=A5A70125627DB09FEDE9AD8D5945EC0622EAB3437B2C3C675EAACAEDB079262DD0535D33F391968FC5374CF745A7D62C&originRegion=eu-west-1&originCreation=20210702191213 (accessed July 3, 2021)."},{"key":"10.1016\/j.amsu.2021.102799_bib37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European dermatology forum consensus in collaboration with the European academy of dermatology and venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.amsu.2021.102799_bib38","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bjd.14285","article-title":"Assessment of adherence to topical corticosteroids in patients with bullous pemphigoid","volume":"174","author":"Sobocinski","year":"2016","journal-title":"The British journal of dermatology"},{"issue":"5","key":"10.1016\/j.amsu.2021.102799_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.amsu.2021.102799_bib40","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/jdv.12153","article-title":"Whole body application of a potent topical corticosteroid for bullous pemphigoid","volume":"28","author":"Jb","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.amsu.2021.102799_bib41","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.amsu.2021.102799_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archderm.139.2.225-a","article-title":"Topical corticosteroids and bullous pemphigoid","volume":"139","author":"Hull","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib44","first-page":"327","article-title":"Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore","volume":"41","author":"Goon","year":"2000","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.amsu.2021.102799_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00276973","article-title":"Mechanisms of STZ y Aloxan inducen damage in rat B cells","volume":"27","author":"Wilson","year":"1984","journal-title":"Diabetologia"},{"key":"10.1016\/j.amsu.2021.102799_bib46","first-page":"125","article-title":"Inhibition of adenosine 3\u2019,5\u2019-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro","volume":"7","author":"Shimoyama","year":"1975","journal-title":"Physiol. Chem. Phys."},{"key":"10.1016\/j.amsu.2021.102799_bib47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib48","unstructured":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial | Elsevier Enhanced Reader, (n.d.). https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S0140673617305603?token=40C13A3DCAD0FE0017029CB05FD06F21CB30B0ADBC8334388EC36EAA4CF007A248E68D01431BEB49CC5829BF087C9FB8&originRegion=eu-west-1&originCreation=20210704082147 (accessed July 4, 2021)."},{"key":"10.1016\/j.amsu.2021.102799_bib49","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/archderm.1977.01640050070009","article-title":"Bullous pemphigoid responding to sulfapyridine and the sulfones","volume":"113","author":"Person","year":"1977","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1346-8138.2005.tb00849.x","article-title":"Childhood bullous pemphigoid successfully treated with diaminodiphenyl sulfone","volume":"32","author":"Motegi","year":"2005","journal-title":"J. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib51","series-title":"Management of Bullous Pemphigoid Recommendations for Immunomodulatory Treatments","author":"Kirtschig","year":"2004"},{"key":"10.1016\/j.amsu.2021.102799_bib52","first-page":"53","article-title":"Bullous pemphigoid and pemphigus vulgaris","volume":"357","author":"Kayani","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.amsu.2021.102799_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002512-200825080-00001","article-title":"Role of methotrexate in the treatment of bullous pemphigoid in the elderly","volume":"25","author":"Patton","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amsu.2021.102799_bib54","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000125","article-title":"Methotrexate side effects: review article","volume":"3","author":"Gaies","year":"2012","journal-title":"J. Drug Metabol. Toxicol."},{"key":"10.1016\/j.amsu.2021.102799_bib55","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"Br. Med. J."},{"key":"10.1016\/j.amsu.2021.102799_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib58","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib59","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.amsu.2021.102799_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.amsu.2021.102799_bib61","first-page":"13","article-title":"Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid","volume":"28","author":"Mazzi","year":"2003","journal-title":"Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapheresis."},{"key":"10.1016\/j.amsu.2021.102799_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"2","author":"Roujeau","year":"1984","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.amsu.2021.102799_bib63","first-page":"269","article-title":"Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature","volume":"12","author":"Chang","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.amsu.2021.102799_bib64","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3389\/fimmu.2019.01477","article-title":"Complement activation in autoimmune bullous dermatoses: a comprehensive review","author":"Edwards","year":"2019","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.amsu.2021.102799_bib65","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"The Journal of biological chemistry"},{"key":"10.1016\/j.amsu.2021.102799_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2","volume":"9","author":"Karsten","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.amsu.2021.102799_bib67","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1074\/jbc.M109.092106","article-title":"The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction","volume":"285","author":"Bamberg","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.amsu.2021.102799_bib68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fimmu.2018.00535","article-title":"Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice","volume":"9","author":"Mihai","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.amsu.2021.102799_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.amsu.2021.102799_bib70","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fimmu.2019.00701","article-title":"NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay","volume":"10","author":"Giusti","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.amsu.2021.102799_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/PTT.S146640","article-title":"Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date","volume":"8","author":"Beck","year":"2018","journal-title":"Psoriasis Targets Ther."},{"issue":"3","key":"10.1016\/j.amsu.2021.102799_bib72","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"The British journal of dermatology"},{"key":"10.1016\/j.amsu.2021.102799_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319865658","article-title":"Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy","volume":"10","author":"Pithadia","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.amsu.2021.102799_bib74","unstructured":"Chmp, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, ((n.d.))."},{"issue":"1","key":"10.1016\/j.amsu.2021.102799_bib75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010033344480","article-title":"Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications","volume":"2","author":"Amerio","year":"2003","journal-title":"Current drug targets. Inflammation and allergy"},{"issue":"3","key":"10.1016\/j.amsu.2021.102799_bib76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)"},{"issue":"1","key":"10.1016\/j.amsu.2021.102799_bib77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/cyto.2000.0791","article-title":"Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation","volume":"13","author":"Engineer","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.amsu.2021.102799_bib78","unstructured":"M. Shrikhande, T. Hunziker, L.R. Braathen, W.J. Pichler, C.A. Dahinden, N. Yawalkar, Increased Coexpression of Eotaxin and Interleukin 5 in Bullous Pemphigoid, ((n.d.))."},{"key":"10.1016\/j.amsu.2021.102799_bib79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fmed.2017.00135","article-title":"Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma","volume":"4","author":"Bagnasco","year":"2017","journal-title":"Frontiers in medicine"},{"issue":"10056","key":"10.1016\/j.amsu.2021.102799_bib80","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.amsu.2021.102799_bib81","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.amsu.2021.102799_bib82","author":"Russo"},{"key":"10.1016\/j.amsu.2021.102799_bib83","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.amsu.2021.102799_bib84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis\u2013a systematic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.amsu.2021.102799_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib86","author":"Morteza"},{"key":"10.1016\/j.amsu.2021.102799_bib87","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.amsu.2021.102799_bib88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.amsu.2021.102799_bib89","doi-asserted-by":"crossref","DOI":"10.5070\/D3274053155","article-title":"Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol. Online J."},{"issue":"5","key":"10.1016\/j.amsu.2021.102799_bib90","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3400","article-title":"Drug Development in Pemphigoid Diseases","volume":"100","author":"Bieber","year":"2020","journal-title":"Acta dermato-venereologica"}],"container-title":["Annals of Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080121007494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2049080121007494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T11:09:41Z","timestamp":1677064181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2049080121007494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":90,"alternative-id":["S2049080121007494"],"URL":"https:\/\/doi.org\/10.1016\/j.amsu.2021.102799","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions","name":"articletitle","label":"Article Title"},{"value":"Annals of Medicine and Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amsu.2021.102799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102799"}}